ArticleClinical and translational science2022

Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.

Neeraj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.